Empty agenda sees UK CSD (Committee on the Safety of Devices) postpone meeting:
This article was originally published in Clinica
One of the most influential UK government bodies on medical devices, the Committee on the Safety of Devices, has postponed its meeting scheduled for November 21 since there were no urgent items on the agenda. The CSD is scheduled to meet every four months. Chairman John Williams decided that as there were no new items for consideration and the number of projects initiated at the last meeting would not be completed nor require input from the CSD until March, that it would be best to postpone the meeting. The next date is scheduled for March 20 2003, with the following meeting being rescheduled from July 17 to June 19 to avoid the holiday period.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.